Summit Therapeutics
NASDAQ · SMMT·Menlo Park, CA·Large-cap·Phase 3
Clinical-stage oncology biopharma developing ivonescimab, a PD-1/VEGF bispecific antibody. BLA submitted to FDA January 2026 (PDUFA Nov 14, 2026); Phase 3 HARMONi-2 and HARMONi-6 in NSCLC.
Decks (1)
| Title | Occasion | Date | Slides | Source |
|---|---|---|---|---|
| Summit Therapeutics J.P. Morgan 2026 Investor Deck | JPM Healthcare | January 12, 2026 | 15 |